🇺🇸 FDA

Intelligence · Clinical Pipeline

Tour Hekla Pipeline

All ClinicalTrials.gov programs at Tour Hekla — phase, modality, and trial IDs.

Programs
12

Quick answer

Tour Hekla has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  2. Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, LVT-001

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial

  3. JNJ-63723283, JNJ-42756493, JNJ-42756493, JNJ-42756493

    Tour Hekla

    Muscle-invasive bladder cancer (MIBC)

    phase 2 small molecule active

    1 trial

  4. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    Treatment of suicidal ideation

    phase 2 small molecule active

    1 trial

  5. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

  6. L-Histidine, L-Histidine monohydrochloride monohydrate, Mannitol, Sucrose, Disodium EDTA dihydrate, Polysorbate 80, Water for injection

    Tour Hekla

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  7. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  8. Propranolol 40 mg film-coated tablets, microcrystalline cellulose

    Tour Hekla

    Prevention of post-traumatic stress disorder

    phase 2 small molecule active

    1 trial

  9. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  11. VAXIGRIPTETRA, suspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivé, à virion fragmenté)

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial

  12. Xarelto 2.5 mg film-coated tablets

    Tour Hekla

    Chronic hemodialysis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Tour Hekla have?

12 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.